Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

    Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

    Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

      Mark Vickery headshot

      Top Stock Reports for Pfizer, Union Pacific & Broadcom

      Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Union Pacific (UNP) and Broadcom (AVGO).

        Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

        Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

          Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive

          AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.

            Bristol-Myers (BMY) Reports Data from CheckMate-214 Study

            Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.

              Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up

              Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.

                Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis

                The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.

                  Pfizer's Xalkori Gets Breakthrough Status for New Indications

                  Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications.

                    Swarup Gupta headshot

                    Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval

                    The Dow endured another volatile week marked by key geopolitical developments.

                      Novartis Gets Approval for Remicade Biosimilar in Europe

                      Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.

                        Pfizer's Tafamadis Gets Breakthrough Therapy Designation

                        Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.

                          Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

                          Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

                            Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

                            Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

                              Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

                              Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

                                Swarup Gupta headshot

                                Dow 30 Stock Roundup: Walmart, Cisco, Home Depot Beat on Earnings

                                The Dow snapped a record streak of wins to traverse a turbulent week.

                                  Roche Tecentriq Combo Achieves Longer Overall Survival Rate

                                  Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

                                    Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

                                    European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

                                      Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

                                      Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

                                        Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y

                                        Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.

                                          What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

                                          Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

                                            Ritujay Ghosh headshot

                                            Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?

                                            Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.

                                              Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?

                                              Both Merck and Pfizer reported upbeat first-quarter results on May 1

                                                Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline

                                                Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.

                                                  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene

                                                  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene